Archive · 2 Jun 2025
Cipla's Bengaluru Plant Receives FDA Inspection Observation
The US Food and Drug Administration (FDA) checked a Cipla Ltd.
factory in Bengaluru to make sure it follows good manufacturing practices.
This inspection happened from May 26th to 30th, 2025.
The FDA gave one observation in a Form 483, which is like a list of things that need to be improved.
Cipla will work with the FDA to fix these issues and respond within a set time.
The inspection is part of ensuring that the factory makes drugs safely and correctly.
Cipla's shares slightly decreased after the announcement.
USFDA conducted a cGMP inspection at Cipla's Bengaluru facility.
The inspection took place between May 26th and 30th, 2025.
The FDA issued one observation in Form 483.
Cipla will work with FDA to address the observation.
Cipla's shares closed slightly lower on the BSE.
- Who
- USFDA and Cipla Ltd
- What
- cGMP inspection at Cipla's Bengaluru facility
- When
- May 26-30, 2025
- Where
- Bommasandra, Bengaluru
- Why
- To ensure the facility complies with manufacturing regulations
- Company
- Cipla Ltd
- Facility Location
- Bommasandra, Bengaluru
- Inspection Dates
- May 26-30, 2025
- Regulatory Body
- USFDA
- Inspection Type
- cGMP
- Form 483 Observations
- One
- Share Price Change
- ₹1,464.85, down ₹11.70 (0.79%)